Predicting outcome in patients with rhabdomyosarcoma: Role of [18F]fluorodeoxyglucose positron emission tomography Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Fluorodeoxyglucose F18
  • Induction Chemotherapy
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Rhabdomyosarcoma, Alveolar
  • Rhabdomyosarcoma, Embryonal

abstract

  • [(18)F]fluorodeoxyglucose positron emission tomography is an early indicator of outcomes in patients with RMS. Future prospective trials may incorporate FDG-PET response data for risk-adapted therapy and early assessment of new treatment regimens.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2014.08.005

PubMed ID

  • 25539372

Additional Document Info

start page

  • 1136

end page

  • 42

volume

  • 90

number

  • 5